Matthew William Rosinack - 30 Jun 2025 Form 3 Insider Report for IOVANCE BIOTHERAPEUTICS, INC. (IOVA)

Role
SVP, Finance (Int. PFO & PAO)
Signature
/s/ Matthew William Rosinack
Issuer symbol
IOVA
Transactions as of
30 Jun 2025
Net transactions value
$0
Form type
3
Filing time
10 Jul 2025, 16:05:15 UTC
Previous filing
21 Jun 2021
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Rosinack Matthew W. SVP, Finance (Int. PFO & PAO) C/O IOVANCE BIOTHERAPEUTICS, INC., 825 INDUSTRIAL ROAD, SUITE 100, SAN CARLOS /s/ Matthew William Rosinack 10 Jul 2025 0001824797

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding IOVA Common Stock 89,129 30 Jun 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding IOVA Stock Options (Right to Buy) 30 Jun 2025 Common Stock 75,000 $25.30 Direct F2
holding IOVA Restricted Stock Units 30 Jun 2025 Common Stock 11,721 Direct F3, F6
holding IOVA Restricted Stock Units 30 Jun 2025 Common Stock 38,287 Direct F4, F6
holding IOVA Restricted Stock Units 30 Jun 2025 Common Stock 59,060 Direct F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 9,089 shares of Iovance Biotherapeutics, Inc.'s (the "Issuer") common stock purchased under the Issuer's 2020 Employee Stock Purchase Plan.
F2 The stock option was granted on September 27, 2021. The shares underlying this option are fully vested.
F3 The restricted stock units ("RSUs") were granted on March 2, 2023. One-third of the RSUs vested on March 2, 2024. The remaining RSUs will vest or have vested in eight equal quarterly installments thereafter.
F4 The RSUs were granted on March 1, 2024. One-third of the RSUs vested on March 1, 2025. The remaining RSUs will vest or have vested in eight equal quarterly installments thereafter.
F5 The RSUs were granted on March 5, 2025. One-third of the RSUs will vest on March 5, 2026. The remaining RSUs will vest in eight equal quarterly installments thereafter.
F6 Each RSU represents a contingent right to receive one share of the Issuer's common stock.

Remarks:

On June 30, 2025, Matthew William Rosinack was appointed as the Issuer's interim Principal Financial Officer and Principal Accounting Officer. Mr. Rosinack has served as the Issuer's Senior Vice President, Finance since September 2021.